An Open-Label Multicenter Study to Evaluate the Impact of Adalimumab on Quality of Life, Health Care Utilization and Costs of Ulcerative Colitis Subjects in the Usual Clinical Practice Setting.

Trial Profile

An Open-Label Multicenter Study to Evaluate the Impact of Adalimumab on Quality of Life, Health Care Utilization and Costs of Ulcerative Colitis Subjects in the Usual Clinical Practice Setting.

Completed
Phase of Trial: Phase III

Latest Information Update: 09 May 2017

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Ulcerative colitis
  • Focus Registrational; Therapeutic Use
  • Acronyms InspirAda
  • Sponsors Abbott Laboratories; AbbVie
  • Most Recent Events

    • 09 May 2017 Results of effect of adalimumab on extraintestinal manifestation presented at the Digestive Disease Week 2017
    • 09 May 2017 Results assessing the effect of adalimumab dose escalation on various outcomes among patients (n=129) with Ulcerative Colitis in clinical practice, presented at the Digestive Disease Week 2017.
    • 04 May 2017 According to an AbbVie media release, data from this trial will be presented at Digestive Disease Week (DDW) 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top